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Abstract
Background: Since the identification in early 2013 of severe disease caused by influenza A(H7N9) virus infection,
there have been few attempts to characterize the full severity profile of human infections. Our objective was to
estimate the number and severity of H7N9 infections in Guangzhou, using a serological study.
Methods: We collected residual sera from patients of all ages admitted to a hospital in the city of Guangzhou in
southern China in 2013 and 2014. We screened the sera using a haemagglutination inhibition assay against a
pseudovirus containing the H7 and N9 of A/Anhui/1/2013(H7N9), and samples with a screening titer ≥10 were
further tested by standard hemagglutination-inhibition and virus neutralization assays for influenza A(H7N9). We
used a statistical model to interpret the information on antibody titers in the residual sera, assuming that the
residual sera provided a representative picture of A(H7N9) infections in the general population, accounting for
potential cross-reactions.
Results: We collected a total of 5360 residual sera from December 2013 to April 2014 and from October 2014 to
December 2014, and found two specimens that tested positive for H7N9 antibody at haemagglutination inhibition
titer ≥40 and a neutralization titer ≥40. Based on this, we estimated that 64,000 (95 % credibility interval: 7300,
190,000) human infections with influenza A(H7N9) virus occurred in Guangzhou in early 2014, with an infection-
fatality risk of 3.6 deaths (95 % credibility interval: 0.47, 15) per 10,000 infections.
Conclusions: Our study suggested that the number of influenza A(H7N9) virus infections in Guangzhou substantially
exceeded the number of laboratory-confirmed cases there, albeit with considerable imprecision. Our study was limited
by the small number of positive specimens identified, and larger serologic studies would be valuable. Our analytic
framework would be useful if larger serologic studies are done.
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Background
A novel avian influenza A(H7N9) virus emerged in early
2013 [1, 2] and caused cases of human infections in
China in spring 2013, and subsequent winter and spring
periods. The first epidemic wave was concentrated in
eastern China, but Guangdong province in southern
China was one of the most heavily affected areas in the
second epidemic wave of H7N9 between December 2013
and April 2014 [3]. In total, 124 severe cases were re-
ported in the first wave and 273 severe cases in the second
wave, across China [3]. Guangzhou, a city with population
12.8 million in 2013, is the provincial capital of Guang-
dong province. The objective of this study was to estimate
the number of human infections with H7N9 virus in
Guangzhou, and infer the severity of human infections on
a per-infection basis.
Methods
Recruitment of participants
We collected residual sera in the First Affiliated Hospital
of Guangzhou Medical University from patients in non-
respiratory diseases wards with no signs of influenza-like
illness at presentation or during hospitalization, and patients
from the routine body check center. Sera were collected in
two phases: 2674 sera were collected from December 2013
to April 2014, and 2686 sera were collected from October
2014 to December 2014.
Laboratory methods
Residual sera were first tested in parallel in each phase,
using haemagglutination inhibition (HI) assay against a
pseudovirus containing the H7 and N9 of A/Anhui/1/
2013(H7N9) using methods previously described [4]. Serum
from a laboratory-confirmed H7N9 case was used as a posi-
tive control. Then, 306 positive samples with HI titer ≥10 on
the pseudovirus assay were further tested with HI and
neutralization assays using live A/Anhui/1/2013(H7N9) vi-
ruses in a BSL-3 laboratory according to the guidelines from
WHO (HI: http://www.who.int/influenza/gisrs_laboratory/
cnic_serological_diagnosis_hai_a_h7n9_20131220.pdf;
MN: http://www.who.int/influenza/gisrs_laboratory/cnic_
serological_diagnosis_microneutralization_a_h7n9.pdf )
using 1 % horse red blood cells. We defined a positive
serum sample as a sample with a titer ≥40 by HI and MN.
Statistical analysis
We analyzed the serological data to infer the cumulative
incidence of influenza A(H7N9) infections, in a Bayesian
framework. In the Bayesian framework, information
brought by new data, in the form of the likelihood func-
tion, is combined with prior information that is specified
in a prior distribution to obtain a posterior distribution
that represents updated knowledge.
We stratified our analyses by age group (0–14, 15–24,
25–54, 55–64 and 65+ years of age) to allow extrapola-
tion of seroprevalence to the underlying population. We
described the weekly probability of a serum being tested
positive (i.e. infected) for each age group as a parameter
that depended on the baseline seroprevalence plus the
seroprevalence due to recent infections. We assumed
that all infected individuals had a rise in titer to ≥40
after a lag of 2 weeks [5], and that titers following infec-
tion waned after 6 months because that occurs following
other infections including human influenza virus infec-
tions [6, 7]. We did not have information on the timing
of infections in the general population, but we did have
information on the timing of laboratory-confirmed cases
which were generally severe and required hospitalization.
We assumed that the risk of severe disease remained a
constant fraction of all infections over the course of the
epidemic, so that the timing of severe cases was indica-
tive of the timing of infections in the general popula-
tion (Additional file 1). Based on these assumptions, we
described the seroprevalence due to recent infections as
a product of the cumulative incidence of recent H7N9
infections and expected scaled seroprevalence based on
the delay between possible infection dates and collection
of sera. Yang et al. [5] reported that before the H7N9 epi-
demic, 9/1129 specimens collected in April-May 2013
from the general population in Zhejiang province were
positive for H7N9 at a HI titer of ≥40. We used this infor-
mation to construct informative priors for the baseline
seroprevalence in each age group at a titer ≥40 based on
the population structure in Guangzhou (Additional file 1).
We used a Jeffrey’s prior, i.e. a beta(0.5, 0.5) distribution,
as a non-informative prior distribution for the cumulative
incidence of infection in each age group. We also con-
ducted a sensitivity analysis using a flat beta(1, 1) prior
instead for the cumulative incidence of infection.
We fitted the model using Markov Chain Monte Carlo
(MCMC) methods with a warm-up period of 30,000 iter-
ations followed by a further 30,000 iterations and five
chains. Posterior estimates of the cumulative incidence
of infection in each age group were then combined using
population weights to provide a single estimate of the over-
all age-standardized cumulative incidence of H7N9 in-
fection in Guangzhou. Given this estimate, we further
estimated the total number of infections in the population.
In a previously published study [8], 16 severe cases of
H7N9 were identified through routine surveillance of
pneumonia of unknown etiology from January 2014 to
March 2014. No severe cases of H7N9 were reported in
Guangzhou from October 2014 to December 2014. In
addition to national surveillance, we conducted a surveil-
lance study in our hospital from March 2014 to August
2014 and found no positive cases of H7N9 in 324 hos-
pitalized patients and 1012 influenza-like illness (ILI)
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cases. We used this information to estimate the risk of
severe case and death following an H7N9 infection. We
used trace plots and the potential scale reduction statis-
tic [9] to confirm that MCMC chains converged and
were well-mixed. All statistical analyses were conducted
using R version 3.1.2 (R Foundation for Statistical Com-
puting, Vienna, Austria).
Results
The age and sex distribution of patients from whom we
collected residual sera is shown in Table 1 and the timing
of sera collection in comparison to the timing of detection
of severe cases in Guangzhou are shown in Fig. 1. Of 306
positive samples with HI titer ≥10 on the pseudovirus
assay, two specimens further tested positive for H7N9
antibody at an HI titer of ≥40 and a neutralization
titer ≥40: a specimen collected on 14 February 2014 from
a 38y woman with HI titer of 1:80 on pseudovirus assay
was positive at an HI titer of 80 and a neutralization titer
of 40, and a specimen collected on 4 April 2014 from a
68y man with HI titer of 1:80 on pseudovirus assay was
positive at an HI titer of 80 and a neutralization titer of
80. In addition, a specimen collected on 7 March 2014
from an 83y woman had HI titer of 1:40 on pseudovirus
assay and was tested positive at an HI titer of 40 but
had a neutralization titer ≤10. There was no report of
recent acute respiratory illnesses in the 3 individuals
with titers ≥40.
We used MCMC to fit our model with a total of
60,000 iterations and 5 chains, and in diagnostic checking
we confirmed that the MCMC runs were well-mixed and
converged. Based on the two specimens that tested
positive for H7N9 antibody at an HI titer of ≥40 and a
neutralization titer ≥40, the posterior distribution (Fig. 2)
indicates that the most credible estimate of the overall
age-standardized cumulative incidence of H7N9 infections
between December 2013 and April 2014 was 0.50 % (95 %
credibility interval, CrI: 0.06, 1.51 %), corresponding to
64,000 (95 % CrI: 7300, 190,000) infections in Guangzhou
(Table 2). Using this as the denominator, and the 16 severe
cases and 11 deaths as the numerators respectively [8],
we estimated that the risk of a severe illness following
infection was 5.2 (95 % CrI: 0.72, 23) per 10,000 infec-
tions while the risk of death following infection was 3.6
(95 % CrI: 0.47, 15) per 10,000 infections. Alternative
assumptions about the waning in antibody titers after
infection led to broadly similar estimates (Table 2). Sce-
nario 3 gave a somewhat lower estimate of the cumula-
tive incidence of infection and higher estimates of risk
of severe case and death following an infection.
In a sensitivity analysis using a beta(1, 1) prior for the
cumulative incidence of infection, we estimated that there
were 59,000 (95 % CrI: 9300, 170,000) infections, and the
risk of death following infection was 3.6 (95 % CrI: 0.60,
14) per 10,000 infections. In another sensitivity analysis in-
cluding the three samples with HI titers of ≥40 as posi-
tives, we estimated that there were 64,000 (95 % CrI: 7400,
190,000) infections, and the risk of death following infec-
tion was 3.5 (95 % CrI: 0.47, 15) per 10,000 infections.
Discussion
In this study we estimated that 64,000 (95 % credibility
interval: 7300, 190,000) humans were infected with influ-
enza A(H7N9) virus in Guangzhou between January 2014
and April 2014, which far exceeds the 20 laboratory-
confirmed infections [8]. It was previously estimated that
the number of cases of symptomatic H7N9 virus infec-
tions could be around 500–1000 times the number of
laboratory-confirmed cases [3, 10], and this is consistent
with our estimates of the numbers of infections albeit with
considerable uncertainty. We are the first to estimate the
infection fatality risk for H7N9, and our estimate of 3.6
deaths (95 % CrI: 0.47, 15) per 10,000 infections places the
severity of H7N9 higher than that of human influenza vi-
ruses for which the fatality risk is around 1 per 10,000 in-
fections but varies considerably by age [11]. The severity
of H7N9 virus infections appears to increase with age
[3, 10], but we did not have sufficient sample size to make
robust age-specific estimates of incidence or severity. We
would anticipate higher incidence of H7N9 infections in
Table 1 Age and sex distribution of residual sera collected from Guangzhou
Characteristic Phase 1 (December 2013 through April 2014) (n = 2660) Phase 2 (October 2014 through December 2014) (n = 2680)
Age group, years
0–14 185 (7.0 %) 140 (5.2 %)
15–24 415 (15.6 %) 445 (16.6 %)
25–54 1137 (42.7 %) 1166 (43.5 %)
55–64 340 (12.8 %) 397 (14.8 %)
≥ 65 583 (21.9 %) 532 (19.9 %)
Sex
Male 1336 (50.2 %) 1240 (46.3 %)
Female 1324 (49.8 %) 1440 (53.7 %)
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adult women and older adult men, based on patterns in
exposure frequency in live poultry markets [12].
Our study is limited by the small number of positive
samples. We used a statistical model to extrapolate from
the small number of positives to a population estimate
of the cumulative incidence of infection, which had very
considerable uncertainty. Because we did not collect de-
tailed patient information such as exposures when obtain-
ing the sera specimens, we were unable to explore risk
factors for infection. Larger serological studies in affected
areas would be worthwhile, and the methods we describe
could provide a framework for analysis of such studies.
However, since larger serologic studies (i.e. with tens of
thousands or even hundreds of thousands of samples)
have not been reported, and to the best of our knowledge
have not been done, our data may provide the only avail-
able population-based estimates of the cumulative inci-
dence of H7N9 infection.
Several limitations concerning study design bear men-
tion. Firstly, as most of our samples from the first sample
collection were obtained before or during the peak inci-
dence of H7N9 cases in Guangzhou and second sample
collection was initiated in October 2014, the population
exposure to influenza A H7N9 may not be optimally cap-
tured. In hindsight, it would have been more ideal to ar-
range collection of sera in April to June 2014, the period
when maximal serological responses to H7N9 exposure
might have been expected. We accounted for the overlap-
ping of epidemic and sera collection in our analysis. Sec-
ondly, instead of analyzing serial cross-sectional residual
sera from hospitals, collecting paired sera before and after
epidemics would allow better identification of recent in-
fections based on rises in antibody titers. However such a
study would be much more complex and challenging than
the one we conducted. Thirdly, collection of sera directly
from the general community, rather than through hos-
pitals, would be preferable if feasible, to minimize
Fig. 2 The prior and posterior distributions of the overall age-standardized
cumulative incidence of H7N9 infections, assuming that antibody titers
wane exactly 6 months (26 weeks) after infection. The most credible
estimate of the overall age-standardized cumulative incidence of
H7N9 infections between December 2013 and April 2014 was 0.43 %
(95 % credibility interval: 0.05, 1.32 %)
Fig. 1 Timing of collection of residual sera from 5340 patients in Guangzhou in two phases (black lines), and the detection of severe cases of
infection with influenza A(H7N9) virus in Guangzhou (gray bars) described in a separate study [8]
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potential selection biases. Fourthly, antibody titers fol-
lowing laboratory-confirmed H7N9 virus infection can
be low, and some infections might have been missed.
One study that followed up severe cases reported that
65.8 % of non-fatal cases had detectable H7N9 antibody,
14 days after illness onset [5]. Finally, while a titer ≥40 is
not conclusive evidence of infection because of the poten-
tial for a small number of people to have cross-reactive
antibody following historical infections with other viruses
[13], we accounted for this baseline seroprevalence in our
model.
Our estimate of the total number of infections, including
mild or asymptomatic infections, is consistent with the in-
formation available from ILI surveillance in Guangzhou. In
national surveillance in the first 10 weeks of 2014 there
were 58,291 ILI cases in sentinel clinics, of whom 1090
cases were tested, and three were positive for H7N9 [8].
While it is not possible to make a population-based esti-
mate of the number of mild cases based only on this infor-
mation, it is clear that the occurrence of ILI due to H7N9
infection in early 2014 was around two orders of magni-
tude lower than the expected occurrence of ILI due to sea-
sonal human influenza activity in a typical epidemic when
perhaps 30 % of ILI cases could test positive for human in-
fluenza. At a population level, 10 to 20 % of persons might
be infected with human influenza viruses during an epi-
demic, and our estimate is consistent with the incidence of
H7N9 infections being two orders of magnitude lower than
this.
The large number of infections estimated in our analysis,
based on a small number of positive sera, implies a sub-
stantial risk of exposure to infection among the local popu-
lation of Guangzhou. Visits to live poultry markets are
common in Guangzhou, with one survey in May–August
2013 finding that 47 % of adult respondents had visited a
live poultry market at least once in the preceding year [12].
A previous serological study in Shenzhen identified sero-
logical evidence of high rates of infection (7.2 % in May
2013 and 14.9 % in December 2013) in poultry workers
but not in the general population, consistent with repeated
occupational exposures [14]. In that study, the absence of
confirmed infections or severe illnesses in poultry workers
with serological evidence of recent infection is also
consistent with most infections being mild. A study in
Beijing estimated very low risks of H7N9 in poultry workers
in Beijing, and did not identify any infections in 1300
person-years of exposure among the general population
from 2013 to 2015 [15].
Conclusion
In conclusion, by estimating the number of human infec-
tions with influenza A(H7N9) virus in Guangzhou between
January 2014 and April 2014, we were able to show that
most infections are not associated with severe disease,
which is consistent with the interpretation of mild H7N9
cases detected through ILI surveillance [3, 10, 16, 17].
However, it is concerning that so many mild infections
have occurred, implying that H7N9 has had many oppor-
tunities to acquire specific adaptations needed for efficient
transmission of H7N9 between humans.
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Table 2 Results of main analyses and sensitivity analyses
Main analysis Sensitivity analysis
Alternative models including 2 specimens
with HI and neutralization titers ≥40
Main model with alternative
prior for cumulative incidence
Main model including three
specimens with HI titers ≥40
Model 1 2 3 4 1 1
Estimated overall
cumulative
incidence, θ (%)
0.43
(0.05, 1.32)
0.52
(0.06, 1.59)
0.17
(0.02, 0.50)
0.41
(0.06, 1.22)
0.40
(0.06, 1.17)
0.43
(0.05, 1.32)
Estimated total
number of
infections
55,385
(6503, 169,010)
66,441
(7572, 204,113)
21,638
(2910, 64,431)
52,507
(7387, 156,391)
51,644
(8091, 149,142)
55,481
(6576, 168,665)
ISR (per 10,000
infections)
5.90
(0.84, 25.11)
5.02
(0.69, 21.68)
14.17
(2.17, 56.43)
5.66
(0.90, 22.40)
5.82
(1.00, 21.71)
5.89
(0.83, 24.83)
IFR (per 10,000
infections)
4.07
(0.54, 17.41)
3.45
(0.44, 15.13)
9.75
(1.41, 39.48)
3.89
(0.58, 15.69)
4.11
(0.68, 15.68)
4.06
(0.54, 17.49)
The main analysis was repeated to compare four alternative assumptions of expected scaled seroprevalence, x ' i. Sensitivity analyses aimed at comparing 1. main
models using Jeffrey’s prior distribution (beta(0.5, 0.5)) versus flat beta prior distribution (i.e. beta(1, 1)) for cumulative incidence, θ, and 2. main models which
considered two sera versus three sera that tested positive for H7N9 at a HI titer of ≥40. Note: All results are expressed in the most credible estimate (95 % credibility
interval), ISR infection-severity risk, IFR infection-fatality risk
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